• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter H. Wiernik, MD

Arch Intern Med. 1976;136(12):1399-1403.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Ten years ago, less than one fourth of patients with acute nonlymphocytic leukemia (ANLL) (acute myelocytic, myelomonocytic erythroleukemia, and monocytic leukemia) achieved complete remission of their disease with conventional or experimental chemotherapy. Today, two thirds or more of patients with that disease will achieve complete remission and, perhaps more importantly, the median duration of complete remission has been substantially improved recently by a combined modality approach to maintenance therapy. The result of these advances is that median survival of all treated patients, and of patients who achieve complete remission in particular, has greatly improved.

Important improvements in supportive care, chemotherapy, and immunotherapy have together resulted in justifiable optimism for the control of ANLL in the foreseeable future.

SUPPORTIVE CARE

Infection Prevention

Infection during induction therapy resulting from granulocytopenia secondary to the disease and/or its therapy has claimed the lives of more than 25% of patients with ANLL before an adequate . . . [Full Text PDF of this Article]

Author Affiliations

Footnotes

Reprint requests to 22 S Greene St, Baltimore, MD 21201 (Dr Wiernik).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?